SETD1B activates iNOS expression in myeloid-derived suppressor cells

Priscilla S. Redd, Mohammed L. Ibrahim, John D. Klement, Sarah K. Sharman, Amy V. Paschall, Dafeng Yang, Asha Nayak, Kebin Liu

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Inducible nitric oxide synthase (iNOS) generates nitric oxide (NO) in myeloid cells that acts as a defense mechanism to suppress invading microorganisms or neoplastic cells. In tumor-bearing mice, elevated iNOS expression is a hallmark of myeloid-derived suppressor cells (MDSC). MDSCs use NO to nitrate both the T-cell receptor and STAT1, thus inhibiting T-cell activation and the antitumor immune response. The molecular mechanisms underlying iNOS expression and regulation in tumor-induced MDSCs are unknown. We report here that deficiency in IRF8 results in diminished iNOS expression in both mature CD11b+Gr1- and immature CD11b+Gr1+ myeloid cells in vivo. Strikingly, although IRF8 was silenced in tumor-induced MDSCs, iNOS expression was significantly elevated in tumor-induced MDSCs, suggesting that the expression of iNOS is regulated by an IRF8-independent mechanism under pathologic conditions. Furthermore, tumor-induced MDSCs exhibited diminished STAT1 and NF-κB Rel protein levels, the essential inducers of iNOS in myeloid cells. Instead, tumor-induced MDSCs showed increased SETD1B expression as compared with their cellular equivalents in tumor-free mice. Chromatin immunoprecipitation revealed that H3K4me3, the target of SETD1B, was enriched at the nos2 promoter in tumor-induced MDSCs, and inhibition or silencing of SETD1B diminished iNOS expression in tumor-induced MDSCs. Our results show how tumor cells use the SETD1B-H3K4me3 epigenetic axis to bypass a normal role for IRF8 expression in activating iNOS expression in MDSCs when they are generated under pathologic conditions.

Original languageEnglish (US)
Pages (from-to)2834-2843
Number of pages10
JournalCancer Research
Volume77
Issue number11
DOIs
StatePublished - Jun 1 2017

Fingerprint

Nitric Oxide Synthase Type II
Neoplasms
Myeloid Cells
Nitric Oxide
Myeloid-Derived Suppressor Cells
Chromatin Immunoprecipitation
T-Cell Antigen Receptor
Epigenomics
Carcinogens
Nitrates
T-Lymphocytes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Redd, P. S., Ibrahim, M. L., Klement, J. D., Sharman, S. K., Paschall, A. V., Yang, D., ... Liu, K. (2017). SETD1B activates iNOS expression in myeloid-derived suppressor cells. Cancer Research, 77(11), 2834-2843. https://doi.org/10.1158/0008-5472.CAN-16-2238

SETD1B activates iNOS expression in myeloid-derived suppressor cells. / Redd, Priscilla S.; Ibrahim, Mohammed L.; Klement, John D.; Sharman, Sarah K.; Paschall, Amy V.; Yang, Dafeng; Nayak, Asha; Liu, Kebin.

In: Cancer Research, Vol. 77, No. 11, 01.06.2017, p. 2834-2843.

Research output: Contribution to journalArticle

Redd, PS, Ibrahim, ML, Klement, JD, Sharman, SK, Paschall, AV, Yang, D, Nayak, A & Liu, K 2017, 'SETD1B activates iNOS expression in myeloid-derived suppressor cells', Cancer Research, vol. 77, no. 11, pp. 2834-2843. https://doi.org/10.1158/0008-5472.CAN-16-2238
Redd PS, Ibrahim ML, Klement JD, Sharman SK, Paschall AV, Yang D et al. SETD1B activates iNOS expression in myeloid-derived suppressor cells. Cancer Research. 2017 Jun 1;77(11):2834-2843. https://doi.org/10.1158/0008-5472.CAN-16-2238
Redd, Priscilla S. ; Ibrahim, Mohammed L. ; Klement, John D. ; Sharman, Sarah K. ; Paschall, Amy V. ; Yang, Dafeng ; Nayak, Asha ; Liu, Kebin. / SETD1B activates iNOS expression in myeloid-derived suppressor cells. In: Cancer Research. 2017 ; Vol. 77, No. 11. pp. 2834-2843.
@article{902ce58687c74ba8b181953ddfe4537b,
title = "SETD1B activates iNOS expression in myeloid-derived suppressor cells",
abstract = "Inducible nitric oxide synthase (iNOS) generates nitric oxide (NO) in myeloid cells that acts as a defense mechanism to suppress invading microorganisms or neoplastic cells. In tumor-bearing mice, elevated iNOS expression is a hallmark of myeloid-derived suppressor cells (MDSC). MDSCs use NO to nitrate both the T-cell receptor and STAT1, thus inhibiting T-cell activation and the antitumor immune response. The molecular mechanisms underlying iNOS expression and regulation in tumor-induced MDSCs are unknown. We report here that deficiency in IRF8 results in diminished iNOS expression in both mature CD11b+Gr1- and immature CD11b+Gr1+ myeloid cells in vivo. Strikingly, although IRF8 was silenced in tumor-induced MDSCs, iNOS expression was significantly elevated in tumor-induced MDSCs, suggesting that the expression of iNOS is regulated by an IRF8-independent mechanism under pathologic conditions. Furthermore, tumor-induced MDSCs exhibited diminished STAT1 and NF-κB Rel protein levels, the essential inducers of iNOS in myeloid cells. Instead, tumor-induced MDSCs showed increased SETD1B expression as compared with their cellular equivalents in tumor-free mice. Chromatin immunoprecipitation revealed that H3K4me3, the target of SETD1B, was enriched at the nos2 promoter in tumor-induced MDSCs, and inhibition or silencing of SETD1B diminished iNOS expression in tumor-induced MDSCs. Our results show how tumor cells use the SETD1B-H3K4me3 epigenetic axis to bypass a normal role for IRF8 expression in activating iNOS expression in MDSCs when they are generated under pathologic conditions.",
author = "Redd, {Priscilla S.} and Ibrahim, {Mohammed L.} and Klement, {John D.} and Sharman, {Sarah K.} and Paschall, {Amy V.} and Dafeng Yang and Asha Nayak and Kebin Liu",
year = "2017",
month = "6",
day = "1",
doi = "10.1158/0008-5472.CAN-16-2238",
language = "English (US)",
volume = "77",
pages = "2834--2843",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - SETD1B activates iNOS expression in myeloid-derived suppressor cells

AU - Redd, Priscilla S.

AU - Ibrahim, Mohammed L.

AU - Klement, John D.

AU - Sharman, Sarah K.

AU - Paschall, Amy V.

AU - Yang, Dafeng

AU - Nayak, Asha

AU - Liu, Kebin

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Inducible nitric oxide synthase (iNOS) generates nitric oxide (NO) in myeloid cells that acts as a defense mechanism to suppress invading microorganisms or neoplastic cells. In tumor-bearing mice, elevated iNOS expression is a hallmark of myeloid-derived suppressor cells (MDSC). MDSCs use NO to nitrate both the T-cell receptor and STAT1, thus inhibiting T-cell activation and the antitumor immune response. The molecular mechanisms underlying iNOS expression and regulation in tumor-induced MDSCs are unknown. We report here that deficiency in IRF8 results in diminished iNOS expression in both mature CD11b+Gr1- and immature CD11b+Gr1+ myeloid cells in vivo. Strikingly, although IRF8 was silenced in tumor-induced MDSCs, iNOS expression was significantly elevated in tumor-induced MDSCs, suggesting that the expression of iNOS is regulated by an IRF8-independent mechanism under pathologic conditions. Furthermore, tumor-induced MDSCs exhibited diminished STAT1 and NF-κB Rel protein levels, the essential inducers of iNOS in myeloid cells. Instead, tumor-induced MDSCs showed increased SETD1B expression as compared with their cellular equivalents in tumor-free mice. Chromatin immunoprecipitation revealed that H3K4me3, the target of SETD1B, was enriched at the nos2 promoter in tumor-induced MDSCs, and inhibition or silencing of SETD1B diminished iNOS expression in tumor-induced MDSCs. Our results show how tumor cells use the SETD1B-H3K4me3 epigenetic axis to bypass a normal role for IRF8 expression in activating iNOS expression in MDSCs when they are generated under pathologic conditions.

AB - Inducible nitric oxide synthase (iNOS) generates nitric oxide (NO) in myeloid cells that acts as a defense mechanism to suppress invading microorganisms or neoplastic cells. In tumor-bearing mice, elevated iNOS expression is a hallmark of myeloid-derived suppressor cells (MDSC). MDSCs use NO to nitrate both the T-cell receptor and STAT1, thus inhibiting T-cell activation and the antitumor immune response. The molecular mechanisms underlying iNOS expression and regulation in tumor-induced MDSCs are unknown. We report here that deficiency in IRF8 results in diminished iNOS expression in both mature CD11b+Gr1- and immature CD11b+Gr1+ myeloid cells in vivo. Strikingly, although IRF8 was silenced in tumor-induced MDSCs, iNOS expression was significantly elevated in tumor-induced MDSCs, suggesting that the expression of iNOS is regulated by an IRF8-independent mechanism under pathologic conditions. Furthermore, tumor-induced MDSCs exhibited diminished STAT1 and NF-κB Rel protein levels, the essential inducers of iNOS in myeloid cells. Instead, tumor-induced MDSCs showed increased SETD1B expression as compared with their cellular equivalents in tumor-free mice. Chromatin immunoprecipitation revealed that H3K4me3, the target of SETD1B, was enriched at the nos2 promoter in tumor-induced MDSCs, and inhibition or silencing of SETD1B diminished iNOS expression in tumor-induced MDSCs. Our results show how tumor cells use the SETD1B-H3K4me3 epigenetic axis to bypass a normal role for IRF8 expression in activating iNOS expression in MDSCs when they are generated under pathologic conditions.

UR - http://www.scopus.com/inward/record.url?scp=85020771653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020771653&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-16-2238

DO - 10.1158/0008-5472.CAN-16-2238

M3 - Article

C2 - 28381543

AN - SCOPUS:85020771653

VL - 77

SP - 2834

EP - 2843

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 11

ER -